FPF
VKTX icon

FNY Partners Fund’s Viking Therapeutics VKTX Stock Holding History

FNY Partners Fund’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,000
Closed -$60K – 479
2017
Q4 		$60K Buy
+15,000
New +$43.6K 0.01% 242

Other funds holding VKTX

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

FNY Partners Fund's VKTX Position: Q1 2018 in Review

FNY Partners Fund sold out of Viking Therapeutics (VKTX) in Q1 2018, closing a stake of 15,000 shares — an estimated $60K sold.

FNY Partners Fund first reported a position in VKTX in Q4 2017 and held it in 1 quarter. The position peaked at $60K in Q4 2017. 66 funds tracked by Wall St. Rank hold VKTX as of Q1 2018.

  • FNY Partners Fund reported no remaining Viking Therapeutics position as of Q1 2018 after selling out during the quarter.
  • FNY Partners Fund sold 15,000 Viking Therapeutics shares in Q1 2018, an estimated $60K.
  • FNY Partners Fund first reported a position in Viking Therapeutics in Q4 2017 and held it in 1 quarter.
  • FNY Partners Fund's Viking Therapeutics position peaked at $60K in Q4 2017.
  • 66 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2018.

Based on FNY Partners Fund's 13F filing for Q1 2018, filed 18 Apr 2018.